11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 01.07.2026 Expectation: 250 pips
Go short on SPX with Fed's updated dot plot
Today at 10:32 AM 27
Period: 25.06.2026 Expectation: 2100 pips
Selling USDJPY with 158.500 in mind amid rising inflation risks
Today at 10:25 AM 11
Period: 25.06.2026 Expectation: 235 pips
ETHUSD sell-off targets $1,500
Today at 09:12 AM 15
Gold sell
Period: 25.06.2026 Expectation: 2100 pips
Sell gold with $4,110 in sight as Fed stays hawkish
Today at 06:40 AM 37
Period: 30.06.2026 Expectation: 400 pips
Покупка USDJPY до уровня 160,00
Today at 05:26 AM 34
Period: 31.12.2026 Expectation: 1800 pips
Invest in SPX with $7,700 in view
Today at 04:47 AM 10
Go to forecasts